KPC

导出PDF

品系基本信息

细胞系名称

KPC

目录号

NM-YD04

品系描述

KPC 细胞是来源于三基因阳性小鼠（Pdx1-cre/LSL-Kras G12D/P53(R172H)）自发胰腺癌肿瘤，在 C57BL/6 小鼠皮下接种后，能正常成瘤。

品系状态

成瘤性验证完成

验证数据

一、细胞形态

在倒置显微镜 10X 情况下拍摄该细胞系形态，如下图所示：

image.png

图一、 KPC 细胞系形态图


二、 C57BL/6小鼠皮下成瘤

Aimage.png

Bimage.png

图二、（A）KPC 细胞系在 C57BL/6小鼠皮下成瘤曲线 ；（B）KPC 细胞系在成瘤过程中小鼠体重变化趋势（n=6）

发表文献 9篇

1. Diabetes reshapes pancreatic cancer-associated endothelial niche by accelerating senescence
发表年份：2025 来源杂志：Nature Communications

2. ABCC10-mediated cGAMP efflux drives cancer cell radiotherapy resistance
发表年份：2025 来源杂志：CELL DEATH AND DIFFERENTIATION

3. cGAS-STING signaling in the tumor microenvironment induces myeloid cell activation and favors T cell-mediated antitumor immunity
发表年份：2025 来源杂志：CANCER BIOLOGY & THERAPY

4. Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development
发表年份：2025 来源杂志：Cell Metabolism

5. Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer
发表年份：2024 来源杂志：JOURNAL OF NANOBIOTECHNOLOGY

6. Tumor-penetrating iRGD facilitates penetration of poly(floxuridine-ketal)-based nanomedicine for enhanced pancreatic cancer therapy
发表年份：2024 来源杂志：JOURNAL OF CONTROLLED RELEASE

7. Tumor Cell Nanovaccines Based on Genetically Engineered Antibody-Anchored Membrane
发表年份：2023 来源杂志：ADVANCED MATERIALS

8. OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment
发表年份：2023 来源杂志：Theranostics

9. Original research: CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model
发表年份：2022 来源杂志：Journal for ImmunoTherapy of Cancer

展开

你也可能感兴趣

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

查看
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

查看